Kymera Therapeutics shareholders elect directors, approve say-on-pay, ratify auditor at 2023 annual meeting

Kymera Therapeutics, Inc.

Elected Bruce Booth, Nello Mainolfi, John Maraganore, Elena Ridloff as Class III directors for three-year terms.
Advisory vote on named executive officer compensation passed with 42.7M for, 1.5M against, 5K abstain.
Ratified Ernst & Young as independent auditor for FY2023 with 46.6M for, 3.2K against.
Broker non-votes: 2.46M on director elections and say-on-pay; none on auditor ratification.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.95

Kymera Therapeutics, Inc. shareholders approved Non-Binding, Advisory Vote on Compensation of the Company's Named Executive Officers at the 2023-06-15 meeting.

Proposal: say on pay
Outcome: passed
Meeting: 2023-06-15

Exact text from the filing

The shareholders of the Company approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.95

Kymera Therapeutics, Inc. shareholders approved Election of Class III Director Nominees at the 2023-06-15 meeting.

Proposal: director election
Outcome: passed
Meeting: 2023-06-15

Exact text from the filing

The shareholders of the Company elected Bruce Booth, D.Phil., Nello Mainolfi, Ph.D., John Maraganore, Ph.D. and Elena Ridloff, CFA as Class III directors of the Company, for a three-year term ending at the annual meeting of shareholders to be held in 2026 and until his or her successor has been duly elected and qualified or until his or her earlier death, resignation or removal.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.95

Kymera Therapeutics, Inc. shareholders approved Ratification of Appointment of Ernst & Young LLP as Independent Registered Public Accounting Firm at the 2023-06-15 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2023-06-15

Exact text from the filing

The shareholders of the Company ratified the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023.

View on SEC.gov

63 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Kymera Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-168977

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.